The specification and use of 18F-FES PET in breast cancer

YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli

doi:10.19401/j.cnki.1007-3639.2023.08.009

Zhongguo aizheng zazhi (Aug 2023)

The specification and use of 18F-FES PET in breast cancer

YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli

Affiliations

YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli: 1. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Center for Biomedical Imaging, Fudan University, Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai 200032, China;2. PET Center, Henan Cancer Hospital, Zhengzhou 450008, Henan Province, China;3. Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China;4. Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China;5. Department of Nuclear Medicine, the Frist Hospital of China Medical University, Shenyang 11000l, Liaoning Province, China

DOI: https://doi.org/10.19401/j.cnki.1007-3639.2023.08.009
Journal volume & issue: Vol. 33, no. 8
pp. 801 – 808

Abstract

Read online

Estrogen receptor (ER) is overexpressed in approximately 2/3 of breast cancer patients’ lesions. Noninvasive detection of ER in vivo and dynamic monitoring of ER are crucial for individualized treatment decision-making. 16α-18F-17β-fluoroestradiol (18F-FES) positron emission tomography (PET) has been used in a variety of preclinical and clinical studies to detect ER expression. However, there is still a lack of technical specifications in China. This technical specification was jointly written by domestic experts who had experience of 18F-FES PET imaging and was formed through consultation based on their own experience and research progress in this field both domestically and internationally. This technical specification introduced the synthesis method and quality control requirements of 18F-FES, recommended its clinical application scenarios, and classified them. In addition, experts’ suggestions were provided throughout the entire process systemically and detailly, including pre-imaging preparation, imaging process, image analysis (normal biological distribution, determination of ER positive and negative, lesion detection, influencing factors, false negative and false positive, report requirements), and the limitations of this imaging technique were proposed. The future application prospects were also discussed. This specification aimed to promote the standardized application of 18F-FES PET in China, achieve repeatability and comparability, and provide important molecular imaging technical support for accurate diagnosis and treatment of breast cancer.

|breast cancer|positron emission tomography|16α-18f-17β-fluoroestradiol|specification|application

Published in Zhongguo aizheng zazhi

ISSN: 1007-3639 (Print)
Publisher: Editorial Office of China Oncology
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.china-oncology.com/EN/1007-3639/home.shtml

About the journal

Abstract

Keywords